Regulators in focus as Amgen launches Singapore biologics plant
This article was originally published in Scrip
Amgen has launched a state-of-the art biologics manufacturing plant in Singapore that required one-quarter of the capital investment of a conventional operation, operates one-third cheaper and took half the time to build. So said CEO and Chairman Bob Bradway, who added that the company plans to build a second one at the same site. But clinical and GMP certifications mean a wait until 2016 before commercial output.
You may also be interested in...
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.
Asia now shoulders 63% of the world’s type 2 diabetes burden, with around 202 million cases in total and a younger onset age than the Western population. Most of these cases are in China and India, while the national prevalence of type 2 diabetes has also increased two-fold or more in many Asian countries, according to data gathered for the 10th International Diabetes Federation-Western Pacific Region held jointly with the 6th Asian Association for the Study of Diabetes in Singapore in late November.